Prevalence and risk of thyroid diseases in myasthenia gravis.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Case-Control Studies
Child
Child, Preschool
Databases, Factual
Female
Humans
Incidence
Infant
Infant, Newborn
Male
Middle Aged
Myasthenia Gravis
/ complications
Prevalence
Probability
Risk Assessment
Socioeconomic Factors
Taiwan
/ epidemiology
Thyroid Diseases
/ epidemiology
Young Adult
cohort studies
comorbidity
myasthenia gravis
neuromuscular diseases
prevalence
risk
thyroid disease
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
11
03
2020
revised:
17
04
2020
accepted:
20
04
2020
pubmed:
25
4
2020
medline:
6
11
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
To estimate the prevalence of thyroid diseases and the cumulative risk of thyroid diseases during a follow-up period after myasthenia gravis (MG) diagnosis compared with non-MG controls. We used the Taiwan National Health Insurance Database linked to Registry of Catastrophic Illness database to identify patients with MG. The controls were composed of those who did not have MG and were matched with the MG patients by sex, age, and the index date. We recorded thyroid disease histories before and after the index date. Our study included 5813 MG patients and 29 065 controls. The prevalence of thyroid diseases in the MG patients at diagnosis was 18.4%, which was nearly 3.9-fold greater than that in the control group. (Odds ratio [OR] 3.895, 95% Confidence interval [CI] 3.574-4.246) After excluding pre-existing thyroid diseases, the incidence of comorbid thyroid diseases was 8.7% in the MG patients and 4% in the control group. The MG patients had a 2.36-fold increased risk of developing thyroid diseases compared to the control group. (crude hazard ratio [HR] 2.360, 95% CI 2.095-2.659) The cumulative probabilities of developing thyroid diseases at 1, 5, and 10 years after the index date were 21.6%, 24.9%, and 28.7%, respectively, in the MG patients, while the cumulative probabilities were 6.5%, 8.8%, and 11.8%, respectively, in control group (log-rank test <0.0001). The current population-based study showed a higher prevalence of pre-existing thyroid diseases and a higher cumulative probability of thyroid diseases during follow-up after MG diagnosis than in the general population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-247Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
NacuA, AndersenJB, LisnicV, OweJF, GilhusNE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015;48(6):362-368.
YehJH, LinCC, ChenYK, SungFC, ChiuHC, KaoCH. Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: a population-based cohort study. Neuromuscul Disord. 2014;24(3):245-249.
TanovskaN, NovotniG, Sazdova-BurneskaS, et al. Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. 2018;6(3):472-478.
MisraUK, KalitaJ, SinghVK, KumarS. A study of comorbidities in myasthenia gravis. Acta Neurol Belg. 2020;120(1):59-64.
TajimaY, YaguchiH, MitoY. Non-motor comorbidity of myasthenia gravis: myasthenia gravis as a systemic immunological disorder involving non-motor systems. Intern Med. 2019;58(9):1341-1347.
OuSM, LiuCJ, ChangYS, et al. Tuberculosis in myasthenia gravis. Int J Tuberc Lung Dis. 2013;17(1):79-84.
Schneider-GoldC, HagenackerT, MelzerN, RuckT. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.
GilhusNE, NacuA, AndersenJB, OweJF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22(1):17-23.
ChristensenPB, JensenTS, TsiropoulosI, et al. Associated autoimmune diseases in myasthenia gravis a population-based study. Acta Neurol Scand. 1995;91(3):192-195.
FangF, SveinssonO, ThormarG, et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med. 2015;277(5):594-604.
YehJH, KuoHT, ChenHJ, ChenYK, ChiuHC, KaoCH. Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: a national population-based study. Medicine. 2015;94(21):e835.
EngelAG. Thyroid function and myasthenia gravis. Arch Neurol. 1961;4(6):663-674.
LangoucheL, Van den BergheG. The dynamic neuroendocrine response to critical illness. Endocrinol Metab Clin North Am. 2006;35(4):777-791.
LinYP, IqbalU, NguyenPA, et al. The concomitant association of thyroid disorders and myasthenia gravis. Transl Neurosci. 2017;8:27-30.
EsfandiariNH, McPheeSJ. Thyroid disease. In: HammerGD, McPheeSJ, eds. Pathophysiology of Disease: an Introduction to Clinical Medicine, 8th ed. New York, NY: McGraw-Hill Education; 2019:609-632.
SongRH, YaoQM, WangB, LiQ, JiaX, ZhangJA. Thyroid disorders in patients with myasthenia gravis: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(10):102368.
HaugenBR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793-800.
HashamA, ZhangW, LotayV, et al. Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun. 2013;44:61-70.
DionisiotisJ, ZoukosY, ThomaidesT. Development of myasthenia gravis in two patients with multiple sclerosis following interferon β treatment. J Neurol Neurosurg Psychiatry. 2004;75(7):1079.
LopomoA, Berrih-AkninS. Autoimmune thyroiditis and myasthenia gravis. Front Endocrinol (Lausanne). 2017;8:169.
KraemerMHS, DonadiEA, TambasciaMA, MagnaLA, PrigenziLS. Relationship between HLA antigens and infectious agents in contributing towards the development of graves' disease. Immunol Invest. 1998;27(1-2):17-29.
GiraudM, BeaurainG, YamamotoAM, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 2001;57(9):1555-1560.
BedoyaSK, LamB, LauK, LarkinJ3rd. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.
ChenYL, YehJH, ChiuHC. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand. 2013;127(3):170-174.
Cacho DiazB, Flores-GavilánP, García-RamosG. Myasthenia gravis and its comorbidities. J Neurol Neurophysiol. 2015;06(05):317.
Szyper-KravitzM, MaraiI, ShoenfeldY. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity. 2005;38(3):247-255.
MaruyamaE, MinamiN, NiinoM, et al. Impact of screening with thyroid ultrasonography in myasthenia gravis patients. Acta Neurol Scand. 2012;125(6):398-402.
SussmanJ, FarrugiaME, MaddisonP, HillM, LeiteMI, Hilton-JonesD. Myasthenia gravis: Association of British Neurologists' management guidelines. Pract Neurol. 2015;15(3):199-206.
GilhusNE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570-2581.
GrobD, BrunnerN, NambaT, PagalaM. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.
GregersenPK, KosoyR, LeeAT, et al. Risk for myasthenia gravis maps to a (151) Pro->Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol. 2012;72(6):927-935.
SandersDB, WolfeGI, BenatarM, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419-425.